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Abstract Biosensors are hybrid analytical devices that amplify
signals generated from the speci¢c interaction between a recep-
tor and the analyte, through a biochemical mechanism. Biosen-
sors use tissues, whole cells, arti¢cial membranes or cell com-
ponents like proteins or nucleic acids as receptors, coupled to a
physicochemical signal transducer. Allosteric enzymes exhibit a
catalytic activity that is modulated by speci¢c e¡ectors, through
binding to receptor sites that are distinct from the active site.
Several enzymes, catalyzing easily measurable reactions, have
been engineered to allosterically respond to speci¢c ligands,
being themselves the main constituent of new-generation biosen-
sors. The molecular basis, robustness and application of alloste-
ric enzymatic biosensing are revised here.
" 2003 Published by Elsevier B.V. on behalf of the Federation
of European Biochemical Societies.
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1. The biosensor concept
Biosensors are hybrid devices that transform chemical in-
formation into an analytically useful signal by means of a
biochemical mechanism [1]. Biosensors consist of a receptor
system, in which a biological component interacts speci¢cally
with a given analyte, and a coupled physicochemical trans-
ducer that ampli¢es the signal resulting from such interaction
from molecular up to macroscopical level (Fig. 1A). The pur-
pose of these constructs is the identi¢cation, quanti¢cation
and eventual screening of speci¢c molecules, as present in
complex mixtures from moderate to very low concentrations.
Therefore, biosensors have utility in analytical research but
also in clinical diagnosis, food and pharmaceutical industry,
environmental control and process monitoring [2]. The inter-
est in biosensor development has partly arisen from the need
of fast and routine analysis of a large number of samples,
what requires robustness, sensitivity and reproducibility
[3,4]. Then, additional features like low cost of production,
miniaturization (for instance as microchips), simple instru-
mentation and automatic sample processing are extremely de-
sirable, especially for everyday food and diagnostic analysis
[5].
The integration of the biological, sensing compound and
the signal transducer into a biosensor can be approached
through multiple ways. In addition, a wide set of available
biological receptors and transducer devices, that are appropri-
ate as sensor components, results in a notable diversity of the
instrumental platform for biosensing technology [6]. Enzymes,
antibodies, membranes, nucleic acids, whole cells and even
tissues are the most used biological receptors for analyte rec-
ognition. On the other hand, electrodes, semiconductors, op-
tical components and microbalances are among the most used
partner transducers. Essentially, these instruments can gener-
ate either optical or electric signals which are very convenient
for instrument development, and the commercial application
of many biosensors in research but also in industry is notice-
able [7].
2. Allosteric enzyme modulation
Allosteric enzymes exhibit regulatable catalytic activities
upon the binding of an e¡ector molecule, to a receptor site
of the enzyme that is di¡erent from the active site. In some
cases, modulation occurs through binding to distinct, alterna-
tive sites, either inhibitory or stimulatory [8]. The mechanics
of allosteric modulation depends on a plastic enzyme archi-
tecture that allows functional £uctuations of the enzyme ac-
tive site, triggered by relatively distant intermolecular interac-
tions [9,10]. These remote e¡ects are caused by the binding to
protein areas with high conformational £exibility [11,12], or
by promoting the association or dissociation of oligomeric
enzymes [13^15], as they can be more active in either as-
sembled or disassembled forms.
Allosteric enzymes that catalyze the formation of easily
detectable products are potential biosensors (Fig. 1B). The
receptor site acts as the recognition element, the active site
as the transducer element and the whole enzyme integrates
both pieces trough its own structure, and transmits the bind-
ing signal via conformational changes. Natural allosteric en-
zymes, however, cannot be directly used as biosensors since
most of their modulators are devoid of analytical interest.
However, it would be possible to incorporate, by modular
engineering, sensing elements to be displayed at speci¢c sites
on the enzyme’s surface, that being ligands for relevant ana-
lytes, would enable the enzyme to catalytically respond to new
e¡ectors. However, as discussed below, the allosteric biosen-
sor prototypes that have been constructed up to now, are the
result of trial-and-error approaches rather than of rational
design.
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3. Enzymes engineered as allosteric biosensors
3.1. L-Galactosidase
Escherichia coli L-galactosidase hydrolyzes lactose to gener-
ate glucose and galactose during the bacterial heterotrophic
growth, but also several lactose analogs producing colored,
luminescent or £uorescent compounds. The availability of
such alternative substrates, specially those that are colorimet-
ric such as 5-bromo-4-chloro-3-indoxyl-L-D-galactopyranoside
(X-gal) or ortho-nitrophenyl L-D-galactopyranoside (ONPG),
has strongly supported the use of this enzyme as reporter for
analysis of gene expression [16], as a marker for gene cloning
and plasmid construction [17] and as partner in fusion pro-
teins for structural stabilization [18], process monitoring [19]
and puri¢cation [20]. Structurally, it is composed by four
identical subunits of 116 000 Da interacting through long
and activating interfaces, and displaying four active sites
formed by mutual protrusion of the activating interfaces
[21]. Among others, the activity of E. coli L-galactosidase is
modulated by Mg2þ [22], by thiol reagents [23] and interest-
ingly by antibodies raised against the enzyme [24], proving a
structurally responsible architecture with potential for bio-
sensing.
Among a series of hybrid enzymes in which an antigenic
peptide of foot-and-mouth disease virus VP1 capsid protein
was displayed in solvent-exposed regions [25,26], two of them
showed relevant up-modulation upon binding of anti-peptide
monoclonal antibodies. Interestingly, in these two allosteric
constructs the viral peptide had been inserted close to the
active site and like in other insertional mutants, their speci¢c
activity was lower than in the wild-type enzyme. The allosteric
enhancement of the hydrolysis rate was titer dependent [27,28]
and occurred either through a reduction of Km or a raise of
kcat [29]. Bivalent antibody binding is not required for activa-
tion, but the simultaneous interaction with antibodies by more
than one enzyme subunit largely expands the catalytic signal
[30]. Although the extent of activation promoted by the anti-
bodies was ¢rstly observed between 1.8- and 2-fold, it was
enlarged up to more than 4-fold (Table 1) by exploring alter-
native reaction conditions combined with multiple insertions
of the antigenic peptide in the enzyme [31]. These extensively
engineered enzymes, displaying up to 12 copies of the peptide,
were highly responsive to sera from virus-infected animals
[32], proving a high sensitivity and robustness for diagnosis
in homogeneous assays. A related series of L-galactosidase
sensors, displaying an antigenic peptide from the human im-
munode¢ciency virus (HIV-1) gp41 structural protein, also
rendered excellent responses in front of human sera when
compared with commercial diagnostic immunoassays [33].
3.2. Alkaline phosphatase
E. coli alkaline phosphatase is an homodimeric, non-speci¢c
 
 
 
 
 
 
 
 
Fig. 1. Generic biosensors (A) are hybrid devices including a biological component acting as the analyte-binding site, and a physicochemical
signal transducer that converts the speci¢c interaction with the analyte into a macroscopic signal. Allosteric enzymatic sensors (B) respond to
speci¢c e¡ectors through variations (generally up to modulation) of the catalysis rate. In these compact biosensors, the enzyme itself contains
both the receptor site and the signal transducer (the catalytic site). The signal is transmitted to the active site by conformational changes trig-
gered by the adaptive binding of the analyte, and the products monitored by standard analytical procedures. In general, the analyte enhances
the speci¢c activity from moderate to high. Ideally, the enzyme biosensor should be inactive but fully activable by the e¡ector.
Table 1
Features or engineered allosteric enzymes for homogeneous immunoassays
Enzyme Modulation
factor
Peptide
lengtha
Catalytic
modi¢cationb
Sensing element E¡ector References
L-Galactosidase 1^4.5 15^45 s Km ; u kcat viral antigenic sites antibodies [26^28,32]
Alkaline phosphatase 0.5^3 13^15 su kcat viral antigenic sites antibodies [33,34]
TEM-1 L-lactamase 0.06^1.7 3^6 steric hindrance
and su kcat
random mimotopes antibodies [35]
TEM-1 L-lactamase 0.77^1.43 6^12 steric hindrance
and su kcat
random paratopes streptavidin, ferritin
and L-galactosidase
[37]
aIn some cases, replacements or partial replacements were done rather than solely insertions. Lengths indicated here refer exclusively to the in-
corporated foreign peptide sequences.
bProven or suspected.
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phosphomonoesterase whose activity is highly appreciated for
analytical purposes because of its colorimetric detection. The
insertion of an HIV peptide from the structural protein gp120
in the vicinity of the active site rendered a fully active enzyme,
but the presence of anti-peptide antibodies inhibited the cata-
lytic rate up to 40^50% [34]. The introduction of either two
independent point mutations in the enzyme, however, inverted
the sensing response by promoting enzyme activation upon
antibody binding (Table 1). The performance of both up-
and down-responsive biosensors was further con¢rmed by us-
ing an antigenic peptide from hepatitis C virus, the resulting
constructs responding consistently with those carrying the
HIV epitope [35].
3.3. L-Lactamase
A bacteriophage-transported TEM-1 L-lactamase was sub-
mitted to random insertional mutagenesis to explore permis-
sive sites for foreign peptide display, and the resulting libraries
are screened by biospanning on immobilized monoclonal anti-
bodies against the prostate speci¢c antigen [36]. The activity
of the isolated enzymes, containing mimotopes for those anti-
bodies, was tested upon antibody binding, showing a general
and quantitatively important down-regulation by steric hin-
drance of the active site. However, the clone P66L4-06 re-
sponded to the monoclonal antibody PSA66 by enhancing
the hydrolysis rate of the substrate Centa up to 1.7-fold and
by a slower catalysis of substrate PADAC (35% of the wild-
type enzyme). The behavior of this particular construct was
probably allosteric, since its enzymatic response was compa-
rable to those of L-galactosidase and alkaline phosphatase
constructs [37]. Further insertional mutagenesis of TEM-1
L-lactamase generated a set of peptide-displaying, hybrid en-
zymes responsive, although at much lesser extent, to non-anti-
body ligands such as streptavidin, ferritin and L-galactosidase
[38].
3.4. Green £uorescent protein (GFP)
Aequorea victoria GFP was modi¢ed to accommodate the
complete sequence of TEM-1 L-lactamase, in a prede¢ned,
solvent-exposed region in the vicinity of the £uorophore
[39]. This construct responded to the binding of the L-lactam-
ase inhibitory protein BLIP by a dramatic increase in £uores-
cence, without changes in the emission spectrum. An end ter-
minal fusion of GFP carrying a complete L-lactamase was not
initially stimulated by BLIP, but after random mutagenesis
several responsive variants were isolated. In general, directed
evolution procedures have been proven useful to improve the
performance of these GFP-derived biosensors [40].
3.5. Neural protease
A recent and rare example of rational design in enzymatic
biosensor development has been inspired in the principle of
intrasteric regulation that rules some natural enzymes [41]. In
a partially synthetic construct containing the Cereus neural
protease, its phosphoramidite inhibitor has been covalently
attached through a short and £exible single-stranded (ss)DNA
hinge, thus blocking the enzyme activity [42]. The presence of
complementary DNA molecules, hybridizing with the hinge
DNA segment and restricting its £exibility, promotes the re-
lease of the inhibitor and switches on the protease. Its activity,
which results then to be dependent on the concentration of
DNA molecules with speci¢c sequence, can be detected by
£uorescence through the hydrolysis of peptidic substrates con-
taining both a £uorophore and a quencher.
4. Ribozymes and allosteric biosensing
Nucleic acids exhibit variations in their catalytic activity
upon binding of di¡erent ligands, especially small organic
e¡ectors [43,44]. This allosteric property can be further en-
hanced by appropriate engineering and exploited for biosen-
sor and biochip construction, mainly based on ribozymes, as
shown in recent particular examples and reviews [45^47].
Although a solely modular rational approach seems to be
not su⁄cient for successful biosensor performance, in combi-
nation with directed molecular evolution it has resulted into
fascinating prototype molecules [48].
5. Concluding remarks
Allosteric enzymatic regulation is very promising as the
basis for fast and reliable diagnosis via targeted molecular
sensing. Both allosteric and non-allosteric enzymes can be
engineered to respond to speci¢c e¡ectors, through variations
(desirably up-modulation) of their speci¢c activity. Interest-
ingly, the enzymatic sensing is ideal for homogeneous assays
and suitable for miniaturization and automatic processing.
Although the up-to-now available prototypes have been
mainly obtained by trial-and-error approaches, there are in-
creasing examples of successful rational design. Furthermore,
both straight protein engineering in the nearby of the active
site, and directed molecular evolution have been proven as
useful technologies to improve the robustness and sensitivity
of enzymatic biosensors. Antibodies, being critical analytes in
the diagnosis of most infectious diseases, are appropriate tar-
gets for allosteric sensing, since their adaptive binding e⁄-
ciently triggers the structural transitions required for enzy-
matic modulation. However, analytes other than antibodies
can also be allosterically detected, proving the enormous po-
tential and wide spectrum of applications of the enzyme-based
biosensing.
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